Recursion Pharmaceuticals (RXRX) Other Gross PP&E Adjustments (2020 - 2025)
Historic Other Gross PP&E Adjustments for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$47.8 million.
- Recursion Pharmaceuticals' Other Gross PP&E Adjustments fell 15141.35% to -$47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.8 million, marking a year-over-year decrease of 15141.35%. This contributed to the annual value of $123.1 million for FY2024, which is 3291.05% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Other Gross PP&E Adjustments is -$47.8 million, which was down 15141.35% from -$50.3 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Other Gross PP&E Adjustments ranged from a high of $123.1 million in Q4 2024 and a low of -$53.2 million during Q1 2025
- For the 5-year period, Recursion Pharmaceuticals' Other Gross PP&E Adjustments averaged around $21.8 million, with its median value being -$17.5 million (2021).
- Per our database at Business Quant, Recursion Pharmaceuticals' Other Gross PP&E Adjustments tumbled by 38651.69% in 2021 and then soared by 488181.29% in 2022.
- Over the past 5 years, Recursion Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at -$1.7 million in 2021, then soared by 4881.81% to $82.8 million in 2022, then rose by 11.85% to $92.6 million in 2023, then surged by 32.91% to $123.1 million in 2024, then crashed by 138.83% to -$47.8 million in 2025.
- Its Other Gross PP&E Adjustments was -$47.8 million in Q3 2025, compared to -$50.3 million in Q2 2025 and -$53.2 million in Q1 2025.